No vaccine interference between bovine coronavirus and bovine herpesvirus-1 in a randomized trial when coadministrating two intranasal modified-live viral vaccines to neonatal calves
American Journal of Veterinary Research · 2024
DOI: 10.2460/ajvr.23.12.0281 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Veterinary Research, 2024. Verfasst von Michael W Bolton und 5 weiteren Autor:innen. Beteiligte Einrichtung: Merck Animal Health, Rahway, NJ. Hauptthemen laut MEDLINE: Herpesvirus 1, Bovine, Administration, Intranasal, Viral Vaccines, Animals, Newborn. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
OBJECTIVE Compare immune responses induced by 2 commercial intranasal (IN) modified-live viral (MLV) vaccines given individually or coadministered and evaluate prevention of infection and lung pathology following bovine herpesvirus-1 (BHV-1) challenge. ANIMALS 36 male Holstein calves (ages, 5 to 12 days). METHODS In a randomized complete block design, each calf received an IN injection of either vaccine diluent (Placebo), an MLV vaccine containing bovine herpesvirus-1 (BHV-1; N3), bovine coronavirus vaccine (BC), or both N3 and BC (BC + N3) with a booster 4 weeks later. Nasal secretions and blood were collected weekly. Three weeks after the booster, the calves were challenged with BHV-1, sampled for virus shedding, and euthanized 10 days later to quantify lung pathology. The study period was September 7, 2020, to April 6, 2021. RESULTS Calves were seropositive for BHV-1 and BC before vaccination. No significant difference in BC-specific serum immunoglobin G and nasal immunoglobin A antibody responses in the BC versus BC + N3 group or BHV-1–specific serum immunoglobin G and nasal immunoglobin A antibody responses in the N3 versus BC + N3 group. Cytokine responses to BHV-1 and BC did not differ among groups. BHV-1 shedding after challenge was significantly reduced in N3 groups versus Placebo and BC. There was a significant reduction in lung pathology in the N3 + BC group versus Placebo. CLINICAL RELEVANCE This study provides evidence an MLV vaccine containing BHV-1 and an MLV BC vaccine can be coadministered to neonatal calves without significantly altering immune responses to the 2 viruses or compromising the prevention of BHV-1 respiratory disease. Calves receiving the BC + N3 vaccine had a significant reduction in lung pathology after BHV-1 aerosol challenge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Merck Animal Health, Rahway, NJ.
- Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, SK, Canada.
- School of Public Health, University of Saskatchewan, Saskatoon, SK, Canada.
Zitieren
APA
Bolton, M. W., Nordstrom, S., Hill, K., Midla, L., Rajamanikam, K., & Griebel, P. J. (2024). No vaccine interference between bovine coronavirus and bovine herpesvirus-1 in a randomized trial when coadministrating two intranasal modified-live viral vaccines to neonatal calves. American Journal of Veterinary Research. https://doi.org/10.2460/ajvr.23.12.0281
Vancouver
Bolton MW, Nordstrom S, Hill K, Midla L, Rajamanikam K, Griebel PJ. No vaccine interference between bovine coronavirus and bovine herpesvirus-1 in a randomized trial when coadministrating two intranasal modified-live viral vaccines to neonatal calves. American Journal of Veterinary Research. 2024. doi:10.2460/ajvr.23.12.0281
BibTeX
@article{Bolton2024,
author = {Bolton, Michael W and Nordstrom, Scott and Hill, Kevin and Midla, Lowell and Rajamanikam, Karthic and Griebel, Philip J},
title = {No vaccine interference between bovine coronavirus and bovine herpesvirus-1 in a randomized trial when coadministrating two intranasal modified-live viral vaccines to neonatal calves},
journal = {American Journal of Veterinary Research},
year = {2024},
doi = {10.2460/ajvr.23.12.0281}
}
EUVIMED